Turn Therapeutics (NASDAQ:TTRX) Posts Earnings Results

Turn Therapeutics (NASDAQ:TTRX) released its earnings results on Tuesday. The company reported ($0.09) EPS for the quarter, Zacks reports.

Turn Therapeutics Trading Down 2.5%

Shares of TTRX traded down $0.08 during midday trading on Wednesday, hitting $3.12. The stock had a trading volume of 11,001 shares, compared to its average volume of 30,389. The stock’s 50-day moving average price is $3.71. The company has a market capitalization of $91.87 million and a price-to-earnings ratio of -44.57. Turn Therapeutics has a fifty-two week low of $2.57 and a fifty-two week high of $26.50.

Hedge Funds Weigh In On Turn Therapeutics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. XTX Topco Ltd purchased a new position in Turn Therapeutics during the 4th quarter worth approximately $99,000. Millennium Management LLC purchased a new stake in shares of Turn Therapeutics in the fourth quarter valued at $377,000. Jane Street Group LLC acquired a new stake in shares of Turn Therapeutics in the fourth quarter worth $68,000. Brown Brothers Harriman & Co. purchased a new position in shares of Turn Therapeutics during the fourth quarter valued at $93,000. Finally, Geode Capital Management LLC purchased a new position in shares of Turn Therapeutics during the fourth quarter valued at $68,000.

Wall Street Analyst Weigh In

Several research firms have issued reports on TTRX. D. Boral Capital restated a “buy” rating and issued a $8.00 price target on shares of Turn Therapeutics in a research report on Tuesday, March 24th. Weiss Ratings assumed coverage on Turn Therapeutics in a research note on Monday, January 5th. They set a “sell (e-)” rating for the company. One analyst has rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average price target of $8.00.

Turn Therapeutics Company Profile

We are a pharmaceutical and medical device development company built around a proprietary platform technology designed to enhance drug performance. Our patented mixing process — commercially referred to as PermaFusion™ (“PermaFusion”) — enables stable suspension of polar, water-soluble active pharmaceutical ingredients (“APIs”) in oil-based carriers without the use of emulsifiers. This innovation reduces the quantity of required API inclusion by improving its bioavailability. Reduced API load reduces the likelihood of adverse events.